重新定义肿瘤学加速审批决定中的可用疗法。

IF 42.1 1区医学 Q1 ONCOLOGY

Journal of Clinical Oncology Pub Date : 2024-10-25 DOI:10.1200/JCO.24.00892

Shruti Rajesh Patel, Maya Ramachandran, Angela Ai, Christopher T Chen

引用次数: 0

摘要

在权衡后续药物的快速审批时，@FDA肿瘤学是否应该承认之前的药物？

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Redefining Available Therapy in Oncology Accelerated Approval Decisions.

When weighing rapid approval for follow-on drugs, should @FDAOncology recognize the drugs that came before?

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Clinical Oncology 医学-肿瘤学

CiteScore

41.20

自引率

2.20%

发文量

8215

审稿时长

2 months

期刊介绍： The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.